科迪亚克科学公司美股招股说明书(2025-12-17版)

Prospectus supplement(To prospectus dated June2, 2023) We are offering 6,956,522 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “KOD.” On December12, 2025, the last reported sale price for ourcommon stock on The Nasdaq Global Market was $23.81 per share. We are a “smaller reporting company” as defined under the federal securities laws and, as such, have elected to comply with certain reduced publiccompany disclosure and reporting requirements. See “Prospectus Supplement Summary—Implications of Being a Smaller Reporting Company.” Public offering price $23.00 (1)See “Underwriting” for a description of the compensation payable to the underwriters. We have granted the underwriters an option to purchase up to an additional 1,043,478 shares of common stock from us at the public offering price, lessunderwriting discounts and commissions, within 30 days from the date of this prospectus supplement. Investing in our common stock involves a high degree of risk. Please read “Risk factors” beginning on page S-6 of thisprospectus supplement and in the accompanying prospectus and the documents incorporated by reference into thisprospectus supplement and the accompanying prospectus. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities ordetermined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is acriminal offense. Entities affiliated with Baker Bros. Advisors LP, or BBA, and one of our directors, Dr.FelixJ. Baker, have indicated an interest in purchasing up to anaggregate of one-third of the shares of the common stock offered in this offering at the price offered to the public. Because indications of interest are notbinding agreements or commitments to purchase, the underwriters may determine to sell more, less or no shares in this offering to BBA, or BBA may The underwriters expect to deliver the shares to purchasers on or about December18, 2025. UBSInvestmentBank Jefferies J.P.Morgan EvercoreISI December16, 2025 Prospectus supplement About this prospectus supplementProspectus supplement summary Prospectus EXPLANATORY NOTEABOUT THIS PROSPECTUSSUMMARY Table of Contents ABOUT THIS PROSPECTUS SUPPLEMENT This document is in two parts. The first part is this prospectus supplement, which describes the terms of this offering of common stock and alsoadds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectussupplement and the accompanying prospectus. The second part, the accompanying prospectus dated June2, 2023, including the documents incorporatedby reference therein, provides more general information about our common stock. Generally, when we refer to this prospectus, we are referring to bothparts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and We have not, and the underwriters have not, authorized anyone to provide you with information different than or inconsistent with theinformation contained in or incorporated by reference in this prospectus supplement, the accompanying prospectus and in any free writingprospectus that we have authorized for use in connection with this offering. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We are not, and the underwriters are not, making an offerto sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in thisprospectus supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and theaccompanying prospectus, and in any free writing prospectus that we have authorized for use in connection with this offering, is accurate only as of the date of those respective documents, regardless of the time of delivery of those respective documents. Our business, financial condition,results of operations and prospects may have changed since the date of those respective documents. You should read this prospectussupplement, the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering, in their entirety before making aninvestment decision. You should also read and consider the information in the documents to which we have referred you in the sections of this We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that isincorporated by reference herein were made solely for the benefit of the parties to such agreement, inc